The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification of a gene expression signature predictive of clinical benefit in patients with advanced mucosal melanoma (MCM) treated with immune checkpoint blockade.
 
Suthee Rapisuwon
Research Funding - Bristol-Myers Squibb
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Immunocore
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Immunocore; Xcovery
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Lee S. Gottesdiener
No Relationships to Disclose
 
Douglas Buckner Johnson
Consulting or Advisory Role - Array Biopharma; Bristol-Myers Squibb; Incyte; Merck; Novartis
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
Travel, Accommodations, Expenses - Genentech
 
Daniel Ying Wang
No Relationships to Disclose
 
Garrett Thomas Graham
No Relationships to Disclose
 
David Goerlitz
No Relationships to Disclose
 
Deborah Berry
No Relationships to Disclose
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Merck; Newlink Genetics/Pharmatech; Novartis; Oncolys BioPharma; Pfizer; Surface Oncology; Werewolf Pharma; X4 Pharma
Research Funding - Bristol-Myers Squibb (Inst)